Yi-Bin Chen, MD

Articles

Future Directions in Chronic GVHD Management

October 9th 2025

Panelists discuss how the future of chronic GVHD management looks promising with advances in graft manipulation strategies, expanded posttransplant cyclophosphamide use, dose optimization studies, oral CSF-1R inhibitors in development, and ongoing phase III trials studying current FDA-approved agents in earlier treatment lines and combination therapies to reduce patient morbidity and improve outcomes.

Insights Into Real-World Evidence in Chronic GVHD

October 9th 2025

Panelists discuss how real-world evidence shows lower response rates and shorter time to next treatment compared to clinical trials due to more advanced patient populations and different monitoring practices, while highlighting the potential value of combination therapies using multiple FDA-approved agents simultaneously despite the lack of formal trial data supporting such approaches.

Case 2: cGVHD With Ocular and Hepatic Involvement

October 2nd 2025

Panelists discuss how a 48-year-old female patient with chronic GVHD involving ocular, hepatic, and skin manifestations presents diagnostic challenges when elevated liver enzymes could indicate disease progression or drug toxicity from belumosudil and axicabtagene ciloleucel, leading to consideration of alternative treatments like mycophenolate or the preference for axicabtagene ciloleucel in patients with prior treatment failures or significant lung involvement despite the lack of head-to-head comparative data.

Treatment Sequencing and Organ-Based Considerations in Chronic GVHD

October 2nd 2025

Panelists discuss how treatment selection for multiorgan chronic GVHD currently relies on trial data, toxicity profiles, and practical considerations like proximity to treatment centers and patient preference for oral vs intravenous therapy, while looking toward future developments in predictive biomarkers that could enable personalized treatment selection and early preemptive intervention before clinical symptoms develop.

Assessment and Early Management After Steroid Failure in Chronic GVHD

September 25th 2025

Panelists discuss how the availability of novel agents has transformed chronic GVHD management by shortening steroid treatment duration to 2 to 3 weeks before adding second-line therapy, with response assessment focusing on dominant organ involvement rather than comprehensive National Institutes of Health criteria, and emphasizing patient-reported outcomes and quality of life measures as essential components of treatment evaluation in clinical practice.

Case 1: Multiorgan cGVHD With Pulmonary Involvement

September 25th 2025

Panelists discuss how a 52-year-old male patient developed multiorgan chronic GVHD 9 months post transplant with skin tightness, joint pain, and pulmonary involvement that showed minimal response to initial prednisone therapy and only moderate improvement after adding ruxolitinib, highlighting the importance of early detection through patient education and regular monitoring including spirometry to prevent irreversible fibrosis.

Novel Mechanisms and Emerging Therapies in Chronic GVHD

September 18th 2025

Panelists discuss how belumosudil works through anti-inflammatory and antifibrotic mechanisms by preventing actin filament polymerization and sequestering transcription factors, while axatilimab-csfr represents a novel approach targeting monocyte and macrophage pathways through CSF-1R blockade to reduce tissue inflammation and fibrosis in patients with chronic GVHD who have failed multiple prior therapies.

Advances in Prevention and Treatment Approvals in Chronic GVHD

September 18th 2025

Panelists discuss how recent FDA approvals of 4 agents (ibrutinib, ruxolitinib, belumosudil, and axatilimab-csfr) have expanded treatment options for chronic graft-vs-host disease, with each drug targeting different mechanisms including BTK inhibition, JAK1/JAK2 inhibition, and ROCK2 pathway modulation, while also noting significant advances in disease prevention strategies.

Practical Advice for Management of Chronic GVHD

February 29th 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.

Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD

February 29th 2024

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

Future Landscape of Chronic GVHD

February 22nd 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

Emerging Agents in GVHD: Axatilimab

February 22nd 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

Third Line Treatment in Chronic GVHD

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

A GVHD Clinical Scenario

February 15th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

Belumosudil for Treatment of Chronic GVHD

February 8th 2024

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.

Ibrutinib in Chronic GVHD

February 8th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

Ruxolitinib in Chronic GVHD

February 2nd 2024

The expert panel explores the approval of ruxolitinib for chronic GVHD based on the REACH3 trial. The panel highlights the trial’s outcomes, long-term follow-up data, and the evolving shift in clinical practices.

Switching to Second Line Treatment in Chronic GVHD

February 2nd 2024

The panel examines the transition from systemic steroids to second-line therapies in chronic GVHD, explore standardized clinical trial definitions and real-world challenges in treating chronic GVHD.

Corticosteroids and Clinical Trial Design in Chronic GVHD

January 25th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the complexities of chronic GVHD management, highlighting recent developments and efforts to reduce reliance on steroids.

Targeted Treatments for GVHD

January 25th 2024

The GVHD experts discuss recent advancements in chronic GVHD treatment, focusing on agents ruxolitinib, ibrutinib, and belumosudil and their mechanisms of action. The panel emphasizes the need for ongoing research and clinical trials to refine treatment strategies.